Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program. Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.
Topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) expected in first half 2025 Cash, cash equivalents and marketable securities...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.145560407569 | 6.87 | 6.87 | 6.48 | 47752 | 6.67995655 | CS |
4 | -0.24 | -3.38028169014 | 7.1 | 7.1 | 6.16 | 46546 | 6.63368222 | CS |
12 | -1.651 | -19.3984255669 | 8.511 | 8.947 | 6.16 | 144759 | 7.7456053 | CS |
26 | 1.07 | 18.4801381693 | 5.79 | 9.18 | 5.016 | 509634 | 7.28770497 | CS |
52 | -2.64 | -27.7894736842 | 9.5 | 11.35 | 5.016 | 579445 | 7.94067457 | CS |
156 | -162.34 | -95.9456264775 | 169.2 | 185.5 | 5.016 | 826549 | 52.50321459 | CS |
260 | -27.94 | -80.2873563218 | 34.8 | 185.5 | 5.016 | 683264 | 61.14149409 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約